1. Introduction {#sec1}
===============

End-stage renal disease (ESRD) is commonly caused by hypertensive nephrosclerosis and chronic glomerular diseases \[[@B1]\] although a causative link between nephrosclerosis and hypertension is yet to be established \[[@B2]\]. Studies have examined modifiable risk factors that contribute to CKD. However, there are strong heritable components in the manifestation of the disease \[[@B3], [@B4]\], with the vast majority of individuals suffering from comorbid conditions, such as hypertension or diabetes \[[@B5], [@B6]\].

Since the advent of genome-wide association studies (GWAS), many novel loci associated with common human diseases have been identified \[[@B7]\], including CKD \[[@B3], [@B8]--[@B10]\]. A genetic polymorphism in shroom family member 3 (*SHROOM3*) has been identified as a CKD susceptibility locus through GWAS. *SHROOM3* is a regulator of epithelial cellular arrangement and planar remodeling \[[@B11]\], which contributes to glomerular filtration barrier integrity \[[@B12]\]. Many studies have suggested that *SHROOM3* plays an important role in mammalian kidney development and human kidney disease through estimated GFR (eGFR). One of these CKD-associated *SHROOM3* variants, rs17319721, has been shown to impact cis-expression and renal allograft fibrosis \[[@B13]\]. Genetic polymorphisms in solute carrier family 7-member 9 *(SLC7A9)* gene, an amino acid transporter in renal proximal tubule cells, cause cystinuria \[[@B14]\], showing an association with GFR \[[@B3], [@B15]\], and have been identified as a risk factor for CKD patients of European ancestry \[[@B8]\]. Variants of cystatin C (*CST3*) have been also shown to impact altered eGFR and kidney disease \[[@B16]\]. Polymorphisms in myosin heavy chain 9 (*MYH9*) gene on chromosome 22 have been shown to be associated with a risk for focal segmental glomerulosclerosis (FSGS), HIV-associated nephropathy CKD with admixed nondiabetic kidney disease, hypertension-associated ESRD, and nondiabetic etiologies of ESRD \[[@B17]--[@B20]\]. The *MYH9* risk polymorphisms are common among African Americans, contributing approximately 40--45% of all ESRD and 70% of nondiabetic ESRD \[[@B21]\].

The United States Renal Data System 2016 \[[@B22]\] reported the prevalence of ESRD to be 2,067 per million with an incidence rate of 370/million/year in the country. Genetic underpinnings of pediatric renal diseases, such as congenital and infantile nephrotic syndromes, are significantly higher in the Kingdom of Saudi Arabia (KSA) than in the Western world \[[@B23]\]. The prevalence of ESRD in KSA has exhibited a rapid increase in the past decades resulting in a rate that exceeds those seen in European and American populations \[[@B24]\]. The incidence and prevalence of CKD in the KSA is estimated to be approximately 1.72 million, equating to about 6% of the population. Out of these, only 7.1% are aware of their disease status, and this unawareness often results in poorer outcomes in such patients \[[@B25]\]. Furthermore, there is a sharp annual increase in the rate of CKD patients who develop ESRD, and this accounts for 2.21% deaths annually \[[@B24]\]. The prevalence of diabetic nephropathy among adult ESRD patients is 42.5% with a mortality rate of 18.6% compared to 6.9% of nondiabetic patients. While ethnicity is thought to play a large role in CKD genetics, very few genotyping studies of established CKD associations have been performed to date in Saudi Arabia and the surrounding regions. Our earlier study \[[@B26]\] highlighted the association of the eight SNPs in these four genetic regions and proposed a statistically significant method of predicting the CKD using FGF23, vitamin D~3~ level, and *MYH9* genotypes \[[@B26]\]. Haplotypes represent a combination of genetic determinants along a single chromosome that are either preserved intact or separated by recombination over time. Haplotypes are commonly used in research to identify a disease-conferring gene or locus. Presently, much interest surrounds the use of genetic association studies, which have an advisedly more powerful study design than the linkage- or family-based studies in localizing susceptibility loci for common diseases that confer moderate risk \[[@B27]\]. Here, we present the haplotype association of these SNPs in 160 Saudi CKD and 189 non-CKD subjects from KSA towards the CKD progression risk assessment.

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

The study included 160 Saudi CKD patients reporting to the Department of Nephrology at the King Fahd Hospital of the University, Al Khobar. Stringent inclusion criteria for both, cases and controls, were followed due to the high prevalence rate of CKD in the Saudi population. Patients with a history of any phosphate wasting disorder, including tumor-induced osteomalacia (TIO), X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and untreated primary hyperthyroidism, and those undergoing renal replacement therapy were excluded from the study. Controls consisted of 189 healthy subjects of Saudi origin without evidence of renal disorders (serum creatinine \<1.4 and \<1.2 mg/dl in men and women, respectively). This study was approved by the Ethical Committee of the Imam Abdulrahman Bin Faisal University and conducted according to the Declaration of Helsinki. Signed written informed consent was obtained from all participants.

2.2. Genotyping Assay {#sec2.2}
---------------------

DNA was isolated from the blood of 349 individuals using QIAamp DNA Mini Kit (Qiagen, USA) as per the manufacturer\'s instructions. Genotyping analysis was performed by ABI TaqMan SNP genotyping assays on 160 CKD patients and 189 controls. Allele-specific TaqMan® PCR technology is a highly sensitive assay and was performed using ABI 7500 Fast real-time PCR. Disease-associated SNPs selected from published articles, namely, rs9992101, rs17319721 (*SHROOM3*), rs4805834 (*SLC7A9*), rs4821480, rs4821481, rs2032487, rs3752462 (*MYH9*), and rs13038305 (*CST3*), were included. An additional 100 coronary artery disease patients with hypertension were genotyped for the *MYH9* (rs4821480, rs4821481, rs2032487, and rs3752462) SNPs.

2.3. E Haplotyping {#sec2.3}
------------------

*MYH9* haplotypes spanning 12--23 introns were reconstructed by 4 tagging SNPs. The haplotypes comprised the four SNP loci of the *MYH9* gene in the order rs4821480 (T/g), rs4821481 (T/c), rs2032487 (C/t), and rs3752462 (C/t). The 4 SNPs were genotyped, and the haplotype blocks were determined using the HaploView 4.2 software that assigned haplotypes into chromosome-specific blocks based on the partition-ligation approach through EM algorithm \[[@B28]\]. To identify the nonrandom association of the eight SNPs by estimates of linkage disequilibrium (LD), each pair of SNPs was computed using the standard D-prime method. Patient population was further stratified into cohorts as CKD (eGFR \> 15) and ESRD (eGFR \< 15) to assess the significance of the haplotype variations.

2.4. Statistical Analysis {#sec2.4}
-------------------------

SPSS version 19 (Chicago, Illinois) was used to complete the statistical analysis. Mutation status was classified as positive or negative qualitatively. The genotype frequencies were tested for Hardy--Weinberg equilibrium among the control subjects.

3. Results {#sec3}
==========

The present study investigated 160 CKD cases, in which 85 were males and 75 were females, with a mean age of 47.68 ± 17.27 years. The baseline characteristics of the study participants are shown in Supplementary [](#supplementary-material-1){ref-type="supplementary-material"}.

TaqMan analysis for genetic variants rs9992101, rs17319721 (*SHROOM3*), rs4805834 (*SLC7A9*), rs4821480, rs4821481, rs2032487, and rs3752462 (*MYH9*), and rs13038305 (*CST3*) was carried out for all samples. The control group was consistent with Hardy--Weinberg equilibrium for all SNPs. The distribution of the analyzed genotype polymorphisms was reported in our previous study \[[@B26]\].

The HaploView analysis results are represented in [Figure 1](#fig1){ref-type="fig"}. Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"} indicate the frequency of various *MYH9* E and *SHROOM3* haplotypes and their association, respectively. A new haplotype "E6"-GTTT is revealed to be significantly associated with the patient cohort (*p*=0.03), stratified CKD cohort (*p*=0.002), and ESRD cohort (*p*=0.0001). The common haplotype GTTC (E4) (*p*=0.0009) was also found to be associated with CKD ([Table 1](#tab1){ref-type="table"}). On further stratification, E6 haplotype was found to be strongly associated with ESRD (*p*=0.0001) in ESRD vs. control and in CKD vs. ESRD (*p*=0.04) analysis.

To validate the new E6 haplotype, an additional 100 CAD patients with hypertension were genotyped for the *MYH9* (rs4821480, rs4821481, rs2032487, and rs3752462) SNPs. Haplotype analysis revealed that the new haplotype was insignificant in the CAD patients. Also, the novel E6 haplotype was still found to be significantly associated (*p*=0.010) when ESRD was compared to the CAD cohort ([Table 1](#tab1){ref-type="table"}).

4. Discussion {#sec4}
=============

CKD is becoming an important health issue worldwide and a major cause for morbidity and mortality. Genetic searches for vital markers of CKD are essential to identify individuals who are at risk for ESRD. Numerous genes have been shown to be associated with CKD. *SHROOM3*, a regulator of epithelial cellular arrangement contributes to glomerular filtration barrier integrity while, *CST3* which is involved in creatinine and cystatin synthesis, is strongly associated with multiple kidney-related traits. The *SLC7A9* gene, which is expressed in renal proximal tubule cells, was shown to be strongly associated with the markers of kidney function, creatinine, and eGFR. *MYH9* gene encodes a protein which is expressed in the glomerular podocyte \[[@B26]\].

*MYH9* gene mutations result in nephritis to varying degrees in Epstein and Fechtner syndromes \[[@B21]\]. *MYH9* SNPs and haplotypes are associated with a risk for T2D and non-T2D nephropathy, lupus nephritis, hypertensive nephropathy, and FSGS \[[@B17], [@B18], [@B20], [@B29]--[@B32]\]. The haplotype analysis of this study shows more combinatorial importance for the *MYH9* gene region than SNPs. Oleksyk et al. \[[@B33]\] reported that the E1 haplotype of the *MYH9* gene region, prominent in sub-Saharan Africa, is probably involved in the increased risk of developing CKD by increasing glomerulosclerosis and proteinuria through activation of nephritis by the deregulation of podocyte function and not by immunological mechanisms. In the present study, the E1 (GCCT) haplotype lacked any association towards CKD or ESRD, contradictory to the findings of Colares et al. \[[@B34]\]. The rare E5 (GCTC) is the only other haplotype carrying the C allele at rs4821481, which was noted in only two of the human genome diversity project populations, with frequencies of 0.02 in Mandenka, a West African ethnic group, and 0.01 in Palestinians \[[@B33]\]. Kopp et al. \[[@B18]\] reported the E2 haplotype prominent in the European, Middle Eastern, and South and Central Asian populations to be protective against renal disease, and Tavira et al. \[[@B35]\] reported the same protective effect in a Spanish cohort. The E2 (TTTC) and E3 (TTTT) haplotypes lacked an association in the present study. Interestingly, the haplotype frequencies of the present study were divergent from those reported from other populations \[[@B33]\]. The E4 and E6 haplotypes were found to be significantly associated with an increased risk of CKD and ESRD, respectively. Even in the stratified groups, ESRD (eGFR \< 15 mL/min/1.73 m^2^) and CKD (eGFR \> 15 mL/min/1.73 m^2^), the E4 (GTTC) was associated with an increased risk of CKD, although the novel haplotype GTTT (*p* = 0.0001) was found to be only associated with ESRD.

The SNPs rs9992101 and rs17319721 located in the *SHROOM3* gene on chromosome 4q21 are closely associated with CKD \[[@B8]\], and the former is in high linkage disequilibrium (LD) with rs17319721. The rs17319721 (A) allele is associated with increased *SHROOM3* transcription and is therefore associated with an increased glomerular filtration rate, thereby increasing the risk for CKD \[[@B3]\]. Both these SNPs and their haplotypes were not associated with a risk of CKD in the present study.

5. Conclusion {#sec5}
=============

CKD is often silent until the advanced stages of the disorder. Thus, many individuals remain unaware until symptomatic uremia is detected, and they begin to suffer from renal ailments. The newly identified haplotype will help identify the patients at risk for quicker progression of CKD towards ESRD. This study will further our understanding of the biological mechanisms of kidney function by identifying loci which may potentially influence metabolic renal functions.
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Supplementary Table 1: baseline characteristics of the total study population and stagewise distribution.

###### 

Click here for additional data file.

![Linkage disequilibrium (LD) analysis. LD patterns between the two *SHROOM* and four *MYH9* SNPs in CKD patients vs. control cohort. The pairwise correlation between the SNPs were measured as *r*^*2*^ and are shown (×100) in each diamond. Coordinates are according to the NCBI build dbSNP 144 (r107). (a) Control vs. patients. (b) CKD vs. ESRD. (c) Control vs. CKD. (d) Control vs ESRD. (e) Control vs. CAD. (f) ESRD vs. CAD.](IJN2019-1095215.001){#fig1}

###### 

Frequency of *MYH9* E haplotypes compared between stratified groups such as CKD, ESRD, and CAD.

  Groups                 Haplotype   Frequency   Chi square               *p* value
  ---------------------- ----------- ----------- ------------------------ -----------
  Control vs. patients   TTTC        0.43        1.075                    0.2998
  TTTT                   0.27        1.461       0.2268                   
  GCCT                   0.23        0.339       0.5603                   
  GTTC                   0.03        10.979      **9 × 10** ^**−4**^      
  TCCT                   0.02        0           0.9923                   
  GTTT                   0.01        4.663       **0.0308**               
  TTT                    0.7         5.295       **0.0214**               
  GCC                    0.24        0.391       0.532                    
  GTT                    0.04        15.934      **6.6 × 10** ^**−5**^    
  TCC                    0.02        0           0.9896                   
                                                                          
  Control vs. CKD        TTTC        0.43        1.718                    0.19
  TTTT                   0.28        1.625       0.2024                   
  GCCT                   0.24        2.613       0.106                    
  GTTC                   0.02        9.492       **0.0021**               
  TCCT                   0.02        0.07        0.7919                   
  TTT                    0.7         7.108       **0.0077**               
  GCC                    0.25        2.584       0.1079                   
  GTT                    0.03        10.934      **9 × 10** ^**−4**^      
  TCC                    0.02        0.067       0.7954                   
                                                                          
  CAD vs. ESRD           TTTC        0.418       0.009                    0.9256
  TTTT                   0.269       3.632       0.0567                   
  GCCT                   0.228       0.551       0.4581                   
  GTTC                   0.038       8.051       **0.0045**               
  GTTT                   0.028       6.615       **0.0101**               
  TCCT                   0.015       0.46        0.4975                   
                                                                          
  Control vs. ESRD       TTTC        0.44        0.294                    0.5876
  TTTT                   0.27        2.968       0.0849                   
  GCCT                   0.22        0.084       0.7723                   
  GTTC                   0.03        15.431      **8.6 × 10** ^**−5**^    
  TCCT                   0.02        0.022       0.8828                   
  GTTT                   0.02        14.495      **1 × 10** ^**−4**^      
  TTT                    0.71        5.181       **0.0228**               
  GCC                    0.22        0.06        0.8066                   
  GTT                    0.05        30.498      **3.34 × 10** ^**−5**^   
  TCC                    0.02        0.021       0.8838                   
                                                                          
  CKD vs. ESRD           TTTC        0.4         0.517                    0.4723
  GCCT                   0.25        2.542       0.1108                   
  TTTT                   0.23        0.26        0.6104                   
  GTTC                   0.06        0.494       0.4821                   
  GTTT                   0.03        4.217       **0.04**                 
  TCCT                   0.02        0.008       0.9302                   
  TTT                    0.63        0.082       0.7747                   
  GCC                    0.26        2.442       0.1181                   
  GTT                    0.09        3.329       0.0681                   
  TCC                    0.02        0.007       0.9338                   
                                                                          
  CAD vs. Control        TTTC        0.436       0.533                    0.4656
  TTTT                   0.298       0.214       0.644                    
  GCCT                   0.228       0.369       0.5435                   
  TCCT                   0.018       0.933       0.3342                   
  GTTC                   0.011       0.154       0.6946                   

###### 

Frequency of *SHROOM3* haplotypes compared between patient stratified by CKD, ESRD, and control cohorts.

  Groups                 Haplotype   Frequency   Chi square   *p* value
  ---------------------- ----------- ----------- ------------ -----------
  Control vs. patients   GG          0.69        0.507        0.4765
  AA                     0.24        1.525       0.2168       
  GA                     0.04        0.035       0.8512       
  AG                     0.03        1.91        0.1669       
                                                              
  Control vs. CKD        GG          0.69        0.563        0.4531
  AA                     0.24        2.098       0.1475       
  GA                     0.04        0.002       0.963        
  AG                     0.03        2.383       0.1227       
                                                              
  Control vs. ESRD       GG          0.69        0.824        0.3639
  AA                     0.23        0.155       0.6939       
  GA                     0.05        1.998       0.1575       
  AG                     0.04        0.052       0.8203       
                                                              
  CKD vs. ESRD           GG          0.66        0.014        0.9052
  AA                     0.27        0.807       0.369        
  GA                     0.05        1.49        0.2222       
  AG                     0.02        1.514       0.2186       
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